Brian Giles is a patent attorney with a practice that focuses primarily on biotechnology patent prosecution, due diligence, and portfolio management. He has a Ph.D. in molecular and cellular biology, with a decade of experience conducting research in the areas of immunogenetics, endocrinology, infectious disease, cardiology, developmental biology, cell biology, and molecular biology.

Brian has worked with dozens of universities and numerous early and growth stage companies to develop patent portfolios individualized for his client’s unique needs and intended markets. Brian has worked to protect a wide variety of technologies, including stem cells, recombinant proteins, synthetic peptides, oligonucleotides, viral vectors, antibodies, immunotherapies, biomarkers, biomaterials, nanoparticles and microparticles, tissue engineering techniques and reagents, diagnostics, medical devices, and therapeutic methods. His experience includes drafting patent applications; preparing invalidity, freedom to operate, and non-infringement opinions; prosecuting U.S. and foreign patent applications; and advising companies and investors during I.P. due diligence.